Fmr LLC boosted its position in Eli Lilly And Co (NYSE:LLY) by 526.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,444,216 shares of the company’s stock after buying an additional 6,255,915 shares during the quarter. Fmr LLC owned approximately 0.69% of Eli Lilly And Co worth $798,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. Abbrea Capital LLC increased its position in Eli Lilly And Co by 15.6% in the third quarter. Abbrea Capital LLC now owns 4,710 shares of the company’s stock worth $505,000 after buying an additional 635 shares during the last quarter. Rafferty Asset Management LLC purchased a new stake in Eli Lilly And Co in the third quarter worth $206,000. FIL Ltd increased its position in Eli Lilly And Co by 16.1% in the third quarter. FIL Ltd now owns 269,891 shares of the company’s stock worth $28,962,000 after buying an additional 37,522 shares during the last quarter. Bahl & Gaynor Inc. increased its position in Eli Lilly And Co by 576.1% in the third quarter. Bahl & Gaynor Inc. now owns 191,400 shares of the company’s stock worth $20,539,000 after buying an additional 163,091 shares during the last quarter. Finally, American International Group Inc. increased its position in Eli Lilly And Co by 7.0% in the third quarter. American International Group Inc. now owns 320,229 shares of the company’s stock worth $34,364,000 after buying an additional 20,925 shares during the last quarter. 76.91% of the stock is owned by institutional investors and hedge funds.
A number of analysts have issued reports on the company. Credit Suisse Group raised Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research report on Wednesday, October 31st. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. JPMorgan Chase & Co. set a $123.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Friday, October 5th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a report on Thursday, September 27th. Finally, BMO Capital Markets raised Eli Lilly And Co from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $107.00 to $130.00 in a report on Thursday, October 4th. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $111.19.
Eli Lilly And Co stock opened at $112.87 on Friday. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. The firm has a market capitalization of $119.57 billion, a PE ratio of 21.02, a P/E/G ratio of 1.76 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the company earned $1.05 earnings per share. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. Analysts anticipate that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 1.99%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is 52.57%.
COPYRIGHT VIOLATION NOTICE: “Fmr LLC Purchases 6,255,915 Shares of Eli Lilly And Co (LLY)” was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.wkrb13.com/2018/11/25/fmr-llc-purchases-6255915-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Asset Allocation
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.